JANX
Income statement / Annual
Last year (2025), Janux Therapeutics Inc's total revenue was $10.00 M,
a decrease of 5.55% from the previous year.
In 2025, Janux Therapeutics Inc's net income was -$113.63 M.
See Janux Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$10.00 M |
$10.59 M |
$8.08 M |
$8.61 M |
$3.64 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.03 M
|
$2.06 M
|
$1.96 M
|
$841.00 K
|
$26.24 M
|
$13.00 K
|
$6.00 K
|
| Gross Profit |
$7.97 M
|
$8.53 M
|
$6.13 M
|
$7.77 M
|
-$22.60 M
|
-$13.00 K
|
-$6.00 K
|
| Gross Profit Ratio |
0.8
|
0.81
|
0.76
|
0.9
|
-6.21
|
0
|
0
|
| Research and Development Expenses |
$125.90 M
|
$68.39 M
|
$54.92 M
|
$53.44 M
|
$26.24 M
|
$3.04 M
|
$3.00 M
|
| General & Administrative Expenses |
$41.77 M
|
$41.05 M
|
$26.14 M
|
$22.26 M
|
$10.33 M
|
$0.00
|
$772.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.77 M
|
$41.05 M
|
$26.14 M
|
$22.26 M
|
$10.33 M
|
$1.79 M
|
$772.00 K
|
| Other Expenses |
-$2.03 M
|
-$2.06 M
|
-$1.96 M
|
-$841.00 K
|
-$26.24 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$165.64 M
|
$107.38 M
|
$79.11 M
|
$74.86 M
|
$10.33 M
|
$4.83 M
|
$3.77 M
|
| Cost And Expenses |
$167.67 M
|
$109.44 M
|
$81.06 M
|
$75.70 M
|
$36.57 M
|
$4.84 M
|
$3.77 M
|
| Interest Income |
$44.04 M
|
$29.85 M
|
$14.69 M
|
$4.03 M
|
$257.00 K
|
$206.00 K
|
$233.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$206.00 K
|
$233.00 K
|
| Depreciation & Amortization |
$2.03 M
|
$2.06 M
|
$1.96 M
|
$841.00 K
|
$113.00 K
|
$13.00 K
|
$6.00 K
|
| EBITDA |
-$111.60 M |
-$66.93 M |
-$56.34 M |
-$62.22 M |
-$32.56 M |
-$6.57 M |
-$3.77 M |
| EBITDA Ratio |
-11.16
|
-6.32
|
-6.97
|
-7.22
|
-8.95
|
0
|
0
|
| Operating Income Ratio |
-15.77
|
-9.34
|
-9.03
|
-7.79
|
-9.05
|
0
|
0
|
| Total Other Income/Expenses Net |
$44.04 M
|
$29.85 M
|
$14.69 M
|
$4.03 M
|
$257.00 K
|
-$1.94 M
|
-$233.00 K
|
| Income Before Tax |
-$113.63 M
|
-$68.99 M
|
-$58.29 M
|
-$63.06 M
|
-$32.67 M
|
-$6.78 M
|
-$4.00 M
|
| Income Before Tax Ratio |
-11.36
|
-6.52
|
-7.21
|
-7.32
|
-8.98
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$113.63 M
|
-$68.99 M
|
-$58.29 M
|
-$63.06 M
|
-$32.67 M
|
-$6.78 M
|
-$4.24 M
|
| Net Income Ratio |
-11.36
|
-6.52
|
-7.21
|
-7.32
|
-8.98
|
0
|
0
|
| EPS |
-1.83 |
-1.28 |
-1.32 |
-1.52 |
-0.79 |
-0.16 |
-0.1 |
| EPS Diluted |
-1.83 |
-1.28 |
-1.32 |
-1.52 |
-0.79 |
-0.16 |
-0.1 |
| Weighted Average Shares Out |
$61.97 M
|
$53.75 M
|
$44.02 M
|
$41.47 M
|
$41.24 M
|
$41.61 M
|
$41.61 M
|
| Weighted Average Shares Out Diluted |
$61.97 M
|
$53.75 M
|
$44.02 M
|
$41.47 M
|
$41.24 M
|
$41.61 M
|
$41.61 M
|
| Link |
|
|
|
|
|
|
|
